A&A Practice · 2019 · 46 citations · 6 references
MedicinePharmacotherapySurgeryCardiothoracic SurgeryCardiovascular PharmacotherapyVascular SurgeryAnticoagulant TherapyAnticoagulation ManagementAnticoagulation TherapyAntithrombotic TherapyAtrial FibrillationThrombosisAdverse Cardiovascular Drug EventsAndexanet Alfa ReversalAnticoagulant PharmacologyAortic Root DiseaseAtrial Fibrillation-related ThromboembolismNatural Anticoagulant ProteinsPerioperative Anticoagulation ReversalSystemic Anticoagulation
Andexanet alfa is a recombinant factor Xa decoy molecule capable of reversing direct and indirect factor Xa-inhibiting anticoagulants. We present an adult patient on apixaban for nonvalvular atrial fibrillation who required urgent reoperative aortic surgery for an aortic root pseudoaneurysm. Apixaban was reversed with andexanet alfa. A second dose of andexanet alfa was required before surgical incision for persistently elevated antifactor Xa levels. Intraoperative management required use of cardiopulmonary bypass (CPB). No major adverse cardiovascular, cerebrovascular, hemorrhagic, or thromboembolic events were observed.
6
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.9K citations · Full text
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah Siegal, John T. Curnutte, Stuart J. Connolly et al. · New England Journal of Medicine · 2015 · 1K citations · Full text
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Deborah Siegal, Genmin Lu, Janet M. Leeds et al. · Blood Advances · 2017 · 74 citations · Full text